(Date:11/6/2009)...,, QUINCY, Mass., Nov. 6 Myrian...biotech developer and manufacturer of renewable b...preferred technology provider Uhde GmbH, one of th... "Uhde"), announced an alliance for the engineerin...,s biobased Succinic Acid plants based on renewabl...
(Date:11/6/2009)...,, CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Onc...lytics" or the "Company") today announced updated ...SIN(R) in patients with sarcomas metastatic to the...Connective Tissue Oncology Society Meeting held in...he poster presentation, entitled "A Phase II Study...
(Date:11/5/2009)...,, GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstC...ced its financial results for the third quarter en... of $3.6 million ($0.04 per share) for the three m...oss of $6.8 million ($0.08 per share) in the compa...eptember 30, 2009, GenVec,s net loss was $14.1 mil...
(Date:11/5/2009)...,, RANCHO CORDOVA, Calif., Nov. 5 /PRNewswire-F... a leading supplier of innovative products for pro...ed results for the first quarter of fiscal 2010. ,... Company reported revenues of $5.2 million, a 15 p...he first quarter a year ago. The Company said the ...
Breaking Biology Technology:Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 2Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 3Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8...e Human and Animal Bio Pharma, Products, Includi...is, CASTLE ROCK, Colo., Aug. 20 AspenBio Pharma,...armaceutical company,dedicated to the development ...ans, reported results for the second quarter ended...ident and CEO, said, "Recent product,development a...
...nced its,plans to seek a listing of at least two o... the Middle East. In a statement released in Abuja.... Val Oji said that "this,was part of a comprehens...nting over the next two years. Chrome recently sig...etroleo Brasileiro S/A, Dedini Industries,de Base ...
...logy, Inc. (OTC Bulletin Board: ACTC) (ACTC) annou...lans to privately offer up to $10,000,000,of senio... timing of the,closing of the offering will be sub...ancing are expected to be used to fund working cap...e technology we expect to acquire in our,pending a...
Other Biology Technology:AspenBio Pharma Reports Second Quarter 2007 Results 2AspenBio Pharma Reports Second Quarter 2007 Results 3AspenBio Pharma Reports Second Quarter 2007 Results 4AspenBio Pharma Reports Second Quarter 2007 Results 5AspenBio Pharma Reports Second Quarter 2007 Results 6AspenBio Pharma Reports Second Quarter 2007 Results 7AspenBio Pharma Reports Second Quarter 2007 Results 8Chrome Group to Seek Listing for Some of its Subsidiaries 2Chrome Group to Seek Listing for Some of its Subsidiaries 3Chrome Group to Seek Listing for Some of its Subsidiaries 4Advanced Cell Technology Announces Proposed Financing 2Advanced Cell Technology Announces Proposed Financing 3NBT/BCIP Chromogen System (SIGNET) from Covance Research Products, Inc
...IND surface is produced by a patented microwave pr...g more consistent, even cell attachment, increased...tachment and growth uunder difficult conditions, i...; CellBIND may provide a more ecominic alternative...
SphingoStrips 10 pk from Echelon Biosciences Inc.
...nnel Cell Lines ,High Quality, Functionally-Valida...ll known for having a critical role in nerve and m...n in pain, CNS and the heart. Drugs that modulate ... areas, such as neuropathic pain, cardiac arrhythm...
Biology Products: